Home / Publication / Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

Publication

Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

Author(s): Jos Lommerse, Diana Clarke, Thomas Kerbusch, Henri Merdjan, Han Witjes, Hedy Teppler, Mark Mirochnick, Edward P. Acosta, Larissa Wenning, Sharon Nachman, Anne Chain

Year: September 8, 2019

Recommended for you

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

Publication

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Webinar

Enabling Personalized Therapy with PBPK Modeling for Pediatric Epilepsy

Case Study

Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at Certara

Video

Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Enabling Personalized Therapy with PBPK Modeling for Pediatric Epilepsy

Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at Certara

Newsletter sign up

Quick links

Solutions

Contact